Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

I Would Say The GDC-0980 Market Meet - People Who Loves Nada Profit??

In Figure 3, Kaplan-Meier DAPT survival curves illustrate improved survival for patients who had methylated MGMT relative to those with unmethylated and unknown MGMT status. This observation is in keeping with other studies. It was not possible for us to make a reasonable analysis of the effect MGMT status on survival based on the dose of cilengitide because of the small numbers of evaluable patients. However, it appears that cilengitide had an impact on survival for patients with unmethylated and methylated MGMT. We observed a median OS of 30 months for the methylated group and 19.1 months for the unmethylated group. This indicates an improvement for both genotypes compared with the results reported from EORTC 26981, in which patients with methylated MGMT who received RT+TMZ had a median OS of 21.7 months compared with 12.7 months for patients with unmethylated MGMT. The use of an integrin antagonist in the treatment of malignant glioma is emerging as a strong complement to RT+TMZ in patients with newly diagnosed GBM. The ability to exploit the novel integrin-mediated signaling cascade brings to bear a new class of compounds for the treatment of this disease. The randomized nature of the current study provides strong support for use of the 2000-mg dose and lays a foundation for the current comparative trials ongoing with cilengitide (CENTRIC). In addition, the different mechanism of action and excellent tolerability may permit use the combination of cilengitide with antivascular endothelial growth factor agents to treat patients with newly diagnosed GBM.15 This work was supported by a grant from the National Institutes of Health (CA-62475). CONFLICT OF INTEREST DISCLOSURES T. Mikkelsen received research funding support from Merck KGaA, and T. Batchelor has acted as a consultant to EMD-Serono (the biopharmaceutical selleck screening library division of Merck KGaA). ""Bevacizumab and sunitinib are standard initial therapy in metastatic renal cell carcinoma (mRCC). Despite common use, the safety and activity of sorafenib in bevacizumab- or sunitinib-refractory mRCC have not been prospectively investigated. Metastatic RCC patients with Response Evaluation Criteria in Solid Tumors (RECIST)-defined disease progression (PD) after treatment with either bevacizumab or sunitinib received twice daily 400 mg of sorafenib in a multicenter, prospective phase 2 study. Dose escalation was permitted in the absence of significant toxicity. The primary endpoint was tumor burden reduction rate, defined as the proportion of patients with ��5% reduction in the sum of RECIST-defined target lesions without other PD. Secondary endpoints included progression-free survival (PFS), duration of response, overall survival, and safety. A 2-stage accrual design was used to test the alternative hypothesis that the tumor burden reduction rate was >20% versus <5%. Forty-eight patients were enrolled. The tumor burden reduction rate was 30% (95% confidence interval [CI], 17%-45%).</div>
Sign In or Register to comment.